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The role of T-lymphocyte subsets in recovery from foot-and-mouth disease virus (FMDV) infection in calves
was investigated by administering subset-specific monoclonal antibodies. The depletion of circulating CD4 or
WC1  T cells was achieved for a period extending from before challenge to after resolution of viremia and
peak clinical signs, whereas CD8 cell depletion was only partial. The depletion of CD4 cells was also
confirmed by analysis of lymph node biopsy specimens 5 days postchallenge. Depletion with anti-WC1 and
anti-CD8 antibodies had no effect on the kinetics of infection, clinical signs, and immune responses following
FMDV infection. Three of the four CD4 T-cell-depleted calves failed to generate an antibody response to the
nonstructural polyprotein 3ABC but generated a neutralizing antibody response similar to that in the controls,
including rapid isotype switching to immunoglobulin G antibody. We conclude that antibody responses to sites
on the surface of the virus capsid are T cell independent, whereas those directed against the nonstructural
proteins are T cell dependent. CD4 depletion was found to substantially inhibit antibody responses to the G-H
peptide loop VP1135-156 on the viral capsid, indicating that responses to this particular site, which has a more
mobile structure than other neutralizing sites on the virus capsid, are T cell dependent. The depletion of CD4
T cells had no adverse effect on the magnitude or duration of clinical signs or clearance of virus from the
circulation. Overall, we conclude that CD4 T-cell-independent antibody responses play a major role in the
resolution of foot-and-mouth disease in cattle.
Foot-and-mouth disease (FMD) is a highly contagious, clin-
ically acute, cytopathic viral disease of wild and domestic clo-
ven-hoofed animals. The causal agent is a member of the
family Picornaviridae and consists of a single-stranded, posi-
tive-sense RNA genome enclosed within a nonglycosylated
icosahedral capsid comprising 60 copies each of the four struc-
tural polypeptides VP1 to VP4 (1). The genome encodes a
unique polyprotein from which the structural and nine non-
structural proteins are cleaved by viral proteases (61). FMD
virus (FMDV) shows high genetic and antigenic variability
such that infection with a virus of one of the seven serotypes
does not confer protection against other serotypes (3). Exper-
imental infection is characterized by a short incubation period
of 1 to 3 days followed by pyrexia, the formation of vesicles,
and a short viremic phase with clinical resolution and virus
clearance coinciding closely with the emergence of serum neu-
tralizing antibodies (3). However, ruminants exposed to virus,
whether vaccinated or not, can carry FMDV in the oropharynx
for years following the resolution of the acute infection (2).
In contrast to the well-defined role of humoral immune
responses, the contribution of T-cell-mediated responses to
immunity and their role in the induction of protective B-cell
responses to FMDV in the natural host species are poorly
understood. Observations of murine infection models indicate
that acute cytopathic viral infections frequently induce T-cell-
independent antibody responses, and it was previously pro-
posed that such rapid responses are required to allow the
control of virus spread through the circulation and to ensure
host survival (5, 22, 38). Borca et al. previously reported that
the protective immune response against FMDV in a murine
experimental model was T cell independent (8). However, a
role for T cells in the induction of antibody responses in ru-
minants has been suggested based on the demonstration of
FMDV-specific CD4 T-cell-proliferative responses following
infection or vaccination with virus or peptide (7, 15, 27). Until
recently, CD8 T-cell responses to FMDV in livestock had
been demonstrated only for infected animals, but the T-cell
proliferation assays employed were unable to demonstrate
whether or not the detected responses were class I major
histocompatibility complex (MHC) restricted (12). Recently,
Guzman et al. (28) used gamma interferon production to dem-
onstrate virus-specific MHC class I-restricted CD8 T-cell re-
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sponses in cattle infected or vaccinated with FMDV, but the
role of these CD8 T cells in immunity to FMDV infection is
still not known. There is an abundant  T-cell population in
ruminants; however, there is no clear consensus on the role of
these cells in immunity to infections (13, 52). FMDV vaccine
antigen has been shown to induce proliferation and cytokine
production in naïve pig  T cells, suggesting that these cells
could contribute to the early immune response to FMD vac-
cination (67).
The three major subpopulations of bovine T lymphocytes
identified in the circulation and secondary lymphoid organs of
cattle can be effectively depleted in vivo by administering the
appropriate mouse monoclonal antibody (MAb) (34, 46). In
the present study, we used mouse MAbs to selectively deplete
CD4, CD8, or WC1 T-lymphocyte subpopulations to in-
vestigate the role of these T-cell subsets in the acute stage of
FMDV infection in naïve cattle.
MATERIALS AND METHODS
Experimental design. A total of 12 cattle, 2 to 4 months of age, were used in
the studies. Animal experimentation was approved by the Institute for Animal
Health (IAH) ethical review board under the authority of a Home Office project
license in accordance with the Home Office Guidance on the Operation of the
Animals (Scientific Procedures) Act of 1986 and associated guidelines. In an
initial experiment, eight cattle were allocated into four pairs, each of which
received either anti-CD4, anti-CD8, anti-WC1, or an isotype-matched control
MAb over a period of 3 days, starting the day before virus challenge. Doses of 3
mg, 21.5 mg, and 21 mg were administered intravenously to each calf on days1,
0 (challenge day), and 1, respectively, giving a total dose of approximately 0.76
mg of antibody per kg body weight. In a second experiment, four cattle were
divided into pairs that received either anti-CD4 or a control MAb over a 4-day
period starting 2 days before challenge. The animals were given 20 mg of MAb
on day 2 and 45 mg on each of the following 3 days, giving a total dose of
approximately 2.58 mg of antibody per kg body weight. Cattle were challenged
with FMDV by subepidermolingual injection of 0.2 ml of 105 50% tissue culture
infective doses into each of two sites with the cattle-adapted type O UKG/34/
2001 strain of the virus. Clinical observations were conducted daily until the
resolution of disease. Clinical signs of FMD and rectal temperatures were scored
(see Table S1 in the supplemental material) using a modified subjective scoring
system based on a method described previously by Quan et al. (53). The right
prescapular lymph node was removed from animals in the second experiment 5
days postchallenge, under sedation and local anesthetic. Clotted blood and
heparinized blood were collected at intervals throughout the study and at post-
mortem on day 30 for animals in experiment 1 and on day 29 for animals in
experiment 2. Prescapular lymph node, mandibular lymph node, and probang
samples were collected at postmortem examination.
MAbs used for depletion. The MAbs used for depletion, which are described
in the proceedings of the First International Workshop on Bovine, Sheep, and
Goat Leukocyte Differentiation Antigens (31), were CC8 (anti-CD4), IL-A11
(anti-CD4), CC63 (anti-CD8), and CC15 (anti-WC1). MAb TRT3, raised against
turkey rhinotracheitis virus, was administered to control animals (17). All MAbs
were murine immunoglobulin G2a (IgG2a), and all of the hybridomas were
produced at the IAH, except IL-A11, which was provided by the International
Livestock Research Institute, Nairobi, Kenya.
Preparation of mononuclear cells from tissue and blood. Mononuclear cells
were prepared from samples of prescapular lymph nodes by slicing the tissue into
small fragments, which were gently teased apart in phosphate-buffered saline
(PBS) containing 5% fetal calf serum. The tissue fragments were then disrupted
through sterile gauze with a syringe. Viable mononuclear cells were isolated from
these lymph node suspensions and from heparinized peripheral blood by diluting
them with an equal volume of PBS and underlying them with 13 ml Histopaque
1077 (Sigma, United Kingdom) before centrifugation at 1,000  g for 30 min at
18°C. Cells at the interface were collected, washed three times with PBS, and
counted, and their viability was assessed by trypan blue staining.
Flow cytometry. Blood and lymph node mononuclear cells were analyzed by
flow cytometry to evaluate the degree of lymphocyte depletion using the follow-
ing MAbs: CC30 (anti-CD4), CC58 (anti-CD8), and CC39 (anti-WC1) (31).
MAb CC37 (anti-CD21) was used as a positive control, and MAb TRT1, raised
against turkey rhinotracheitis virus, was used as an isotype-matched negative
control (17, 31). All MAbs were murine IgG1 produced at the IAH. Preliminary
studies using blood and lymph node mononuclear cells from noninfected animals
confirmed that the incubation of cells with the MAbs used for depletion for 20 h
did not block the staining by IgG1 MAbs of the respective specificities used for
subsequent staining of the cells. Cell suspensions were stained with MAbs as
described previously (32, 34) except that a goat anti-mouse isotype-specific sec-
ondary antibody (Alexa Fluor; Molecular Probes, United Kingdom) was used.
Cells were gated for viability based on their forward-scatter and side-scatter
profiles. A minimum of 10,000 viable cells were analyzed in each sample; in
addition, 100,000 viable peripheral blood mononuclear cells were analyzed on
day 1 in experiment 1 and on days 0 and 4 in experiment 2 to assess CD4 T-cell
depletion. Cells were analyzed using a Becton Dickinson FACSCalibur appara-
tus with Cellquest software, and results were analyzed using FCS Express, ver-
sion 3 (De Novo Software).
Immunofluorescence confocal microscopy. Prescapular lymph node samples
were snap-frozen in OCT compound (Tissue-Tek) and stored at 80°C until
being processed. Ten acetone-fixed cryosections from different regions of the
prescapular lymph nodes of each animal were labeled with the following murine
MAbs: CC30 (anti-CD4), MM1A (anti-CD3, IgG1), CC51 (anti-CD21, IgG2b)
(31), and isotype-matched control MAbs TRT1 and AV29 (a MAb directed
against chicken CD4 antigen, IgG2b) (37). Stack images were analyzed to detect
CD4 T-cell depletion. Preliminary studies of prescapular lymph node samples
from noninfected animals showed that the activity of MAb CC30 was not blocked
by the respective MAbs used for CD4 cell depletion. Acetone-fixed cryosec-
tions of mandibular lymph nodes were labeled with IB11, a murine MAb shown
to be specific for conformational, nonneutralizing epitopes of the FMDV capsid
(35), in combination with CC51, dark-zone follicular dendritic cell marker D46
(anti-ovine fibrinogen, IgG2a) (39), and isotype-matched control MAbs TRT1,
TRT3 (IgG2a) (17), and AV29. All MAbs used for confocal microscopy were
produced at the IAH. Goat anti-mouse Molecular Probes Alexa Fluor-conju-
gated secondary antibodies (Invitrogen, United Kingdom) were used for detec-
tion. All data were collected sequentially using a Leica SP2 scanning laser
confocal microscope.
Quantitative rRT-PCR. A quantitative real-time reverse transcription (rRT)-
PCR method was used to quantify the FMDV genome copies in serum and in
probang samples (53, 54, 56). A standard RNA dilution series of the internal
ribosomal entry site of FMDV O/UKG/34/2001 was included on the plate for
reverse transcription, which was performed as previously described (53, 55).
rRT-PCR was performed using an MX3005P sequence detection system (Strat-
agene, United Kingdom) with primers SA-UK-IRES-248F and SA-UK-IRES-
308R and a UK-IRES-271T TaqMan minor groove binding probe (Applied
Biosystems, United Kingdom) as previously described (53). Fifty PCR cycles
were carried out, and samples that did not have a detectable signal above the
threshold after 50 cycles were taken to be negative (53). Samples with threshold
cycle values greater or equal to 39 were designated “borderline” and were
subsequently retested to confirm their positive or negative status (56).
Virus isolation and antigen detection ELISA. The presence of virus in serum
and in probang samples was determined by inoculation of monolayers of primary
bovine thyroid cells (63) and examination for a cytopathic effect (CPE) 24, 48,
and 72 h postinoculation. An enzyme-linked immunosorbent assay (ELISA) was
used to confirm the presence of FMDV in cultures showing CPE (23). Replicates
of bovine thyroid cell culture supernatants from samples showing no sign of CPE
after 72 h postinoculation were pooled and repassaged once to confirm their
positive or negative status.
Virus-neutralizing antibody test. Serum samples were examined for anti-
FMDV neutralizing antibodies as described in the Office International des
Epizooties Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (48a).
Sera with titers greater than or equal to 1/45 were considered to be positive.
Isotype-specific ELISA for detection of anti-FMDV antibodies. An anti-
FMDV sandwich ELISA was used to measure specific IgG1, IgG2, and IgM
levels in serum samples (45). Ninety-six-well Maxisorb Nunc Immunoplates
(Sigma, United Kingdom) were coated overnight with a solution of rabbit anti-
FMDV serotype-specific hyperimmune antiserum (1:5,000) in 0.1 M carbonate-
bicarbonate buffer. Coated plates were incubated with pretitrated inactivated O1
Manisa FMDV whole viral antigen in excess. Duplicate threefold dilution series
of each serum sample were added at a starting dilution of 1/50. Antibody isotypes
were detected using MAbs to bovine IgG1 (B37), IgG2 (B192), and IgM (B67)
obtained from the Department of Veterinary Medicine, Bristol University, fol-
lowed by horseradish peroxidase-conjugated rabbit anti-mouse IgG (DakoCyto-
mation, United Kingdom), which was followed by the addition of O-phenylene-
diamine dihydrochloride (Sigma, United Kingdom). To avoid competition
between IgM and IgG, all samples destined for anti-IgM analysis were first
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absorbed on plates coated with goat anti-bovine IgG (1 mg/ml; Southern Biotech,
United Kingdom) and then transferred onto the viral-antigen-coated plates.
Optical densities (ODs) were read at 492 nm on a MRX Dynex Technologies
reader. Wells were considered positive only if they were greater than 1.5 times
the mean background OD for that dilution. Antibody titers were expressed as the
reciprocal of the last positive dilution.
3ABC nonstructural protein ELISA. Serum samples were examined for the
presence of antibodies directed against the nonstructural 3ABC protein of
FMDV by using the commercially available Ceditest FMDV-NS (Cedi-Diagnos-
tic). Samples were considered to be positive if the percentage of inhibition was
50 (64).
Indirect peptide ELISA. Serum samples from animals in both experiments
receiving anti-CD4 or TRT3 MAbs were examined for the presence of antibodies
directed against the VP1135-156 G-H loop on the surface of FMDV capsids. A
peptide encompassing amino acid residues 135 to 156 of FMDV O UKG/34/2001
(KYGESPVTNVRGDLQVLAQKAA) was kindly produced by L. Hunt, IAH.
A second peptide, kindly provided by V. Fowler, IAH, encompassing the same
residues of FMDV O1BFS (RYSRNAVPNLRGDLQVLAQKVA) was used for
analysis to confirm that our results were consistent with previously published
data (24). The indirect peptide ELISA was performed as previously described
(24), with modifications. Ninety-six-well Maxisorb Nunc Immunoplates (Sigma,
United Kingdom) were coated overnight at 4°C with 100 l/well peptide in PBS,
washed in PBS-Tween 20, and blocked with PBS containing sodium casein
(Sigma, United Kingdom) at 1 mg/ml. This step and all subsequent incubation
steps were carried out at 37°C for 1 h. Sera were added in duplicate at 50 l per
well starting at a 1/50 dilution with tripling dilutions in PBS-sodium casein,
incubated, washed, and detected with horseradish peroxidase-conjugated goat
anti-bovine IgG (Southern Biotech, United Kingdom). Plates were washed and
visualized with O-phenylenediamine dihydrochloride (Sigma, United Kingdom).
Reactions were stopped by the addition of 1.84 M sulfuric acid to the medium,
and the absorbance was read at 490 nm on a MRX Dynex Technologies reader.
Wells were considered to be positive only if they were greater than 1.5 times the
mean background OD for that dilution. Antibody titers were expressed as the
reciprocal of the last positive dilution.
Statistical analysis. To investigate the effect of immune cell depletion on the
titers of FMDV-specific antibody measured by the Ig isotype-specific ELISA, a
Gompertz function was used to describe the antibody titer, Y, as a function of
time, log10(Y)  exp{exp[	(t  )]}, where  is the upper asymptote (i.e.,
maximum titer), 	 is the rate of increase in titer, and  is a delay parameter. The
parameters , 	, and  were estimated using least-squares regression. Parallel
curve analysis (57) of the data from individual animals was used to identify
significant (P
 0.05) differences in the parameters among treatment groups (i.e.,
TRT3, anti-WC1, anti-CD4, and anti-CD8 groups), starting from a model in
which all parameters differed among animals.
RESULTS
Efficiency of T-cell subset depletion. The administration of
anti-CD4 MAb resulted in a rapid reduction in the percentage
of circulating CD4 cells within 24 h, from 11% and 10.8% to
0.15% and 0.17% for the two animals (animals RZ53 and
RZ54, respectively) in experiment 1 and from 18.4% and 26%
to 0.02% and 0.17% for the two animals (animals VT74 and
VT75, respectively) in experiment 2. This depletion was con-
firmed by analysis of 100,000 viable cells in duplicate collected
from experiment 1 animals on day 1 postinfection (0.04 and
0.05% CD4 cells for animal RZ53 and 0.04 and 0.04% CD4
cells for animal RZ54) and in triplicate for experiment 2 ani-
mals on days 0 and 4 postinfection (mean values [ standard
deviations] of 0.05% [0.02] CD4 cells for animal VT74 and
0.04% [0.01] CD4 cells for animal VT75 on day 0 and
0.06% [0.01] CD4 cells for animal VT74 and 0.03% [0.01]
CD4 cells for animal VT75 on day 4). Depletion was main-
tained for 7 days postinfection, with percentages of CD4 cells
consistently below or equal to background nonspecific binding
detected with the isotype control MAbs, after which the num-
bers of CD4 cells gradually increased (Fig. 1). A similar level
and a similar duration of depletion were observed following
FIG. 1. Effect of MAb administration on the percentage of T-lym-
phocyte subpopulations in peripheral blood. (a to c) Experiment 1
animals and MAbs administered over 3 days starting the day before
FMDV challenge. (a) Percentage of CD4 cells in anti-CD4 MAb-
treated animals (animals RZ53 and RZ54) and a control animal (an-
imal RZ57). (b) Percentage of WC1 cells in anti-WC1 MAb-treated
animals (animals RZ51 and RZ52) and a control animal (animal
RZ57). (c) Percentage of CD8 cells in anti-CD8 MAb-treated ani-
mals (animals RZ55 and RZ56) and a control animal (animal RZ57).
(d) Percentage of CD4 cells of experiment 2, with anti-CD4 MAb-
treated animals (animals VT74 and VT75) and a control animal (an-
imal VT77). MAbs were administered over 4 days starting 2 days
before FMDV challenge.
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treatment with anti-WC1 MAb: the numbers of circulating
WC1 cells in the two animals (animals RZ51 and RZ52) in
experiment 1 decreased from 11.7% and 22.3% on day 1 to
0.06% and 0.06% on day 0, respectively, and maintained at
these low levels until day 7 (Fig. 1). In contrast, treatment with
anti-CD8 MAb resulted in a more gradual and only partial
depletion; the numbers of circulating CD8 cells in the two
treated animals (animals RZ55 and RZ56) decreased from
4.0% and 9.4% on day 1 to 3.1% and 5.7% on day 0 and to
1.3% and 4% on day 7, respectively (Fig. 1). There were no
major changes in the proportions of the T-cell subsets (or
CD21 B cells) in animals receiving the control antibody,
although some fluctuation in the percent representation of
each subset was observed during the course of the studies (see
Fig. S1 in the supplemental material). In addition, in the anti-
CD4, anti-WC1, and anti-CD8 MAb-treated animals, there
were no major changes in the proportion of the T-cell subsets
not targeted for depletion or CD21 B cells, consistent with
the specificity of these MAbs (see Fig. S2 and S3 in the sup-
plemental material) (31). Immunohistological examination of
sections of prescapular lymph nodes surgically removed from
experiment 2 animals on day 5 postinfection demonstrated the
absence of CD4 cells throughout the node, including the
cortex and follicles (Fig. 2), paracortical area, and medullary
cords and sinuses (data not shown) of both anti-CD4 MAb-
treated animals. These analyses used both 10 separate sections
and stacking of images from the confocal microscopy exami-
nations to confirm that the CD4 cell depletion was indeed
found throughout the node. These findings were supported by
flow cytometry analysis of lymph node cell suspensions in
which the percentages of CD4 T cells were comparable to
that detected with the isotype control MAbs (data not shown).
By 29 days postinfection, lymph node cell suspensions obtained
following slaughter of these two animals contained 12.4% and
16.4% CD4 cells compared to 38.7% and 32.4% CD4 cells
in lymph node samples from the two control animals.
Effect of lymphocyte depletion on development of clinical
FMD. The clinical scores for all animals following FMDV
infection, representing a measure of the induction, severity,
and resolution of clinical signs, are displayed in Fig. 3. All
cattle succumbed to disease within 1 to 3 days postchallenge.
There was no adverse effect of the depletion of any of the
T-cell subsets on the onset, magnitude, or resolution of clinical
signs following infection.
Effect of lymphocyte depletion on viral clearance. All ani-
mals were confirmed to be viremic 24 h postinfection by virus
isolation and rRT-PCR. The results of daily quantitative mea-
surements of viral genome in serum using rRT-PCR are pre-
FIG. 2. Effect of anti-CD4 MAb injection on the target cell population in lymphoid tissue. Shown are immunofluorescence confocal microscopy
images of prescapular lymph node cortices from experiment 2 anti-CD4 MAb-injected animals (animals VT74 and VT75) and a TRT3 control
MAb-injected animal (animal VT77) biopsied at 5 days postinfection. (a to c) CD4 lymphocytes are green, and CD21 cells are red. (d to f) CD3
lymphocytes are green, and CD21 cells are red. Scale bars, 40 m.
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sented in Fig. 4. High levels of viral genome were detected in
serum collected on days 1, 2, and 3 in all groups of animals, and
levels subsequently declined in all groups. Viral genome was
no longer detectable in all except two animals, one control and
one CD8 T-cell-depleted animal, by day 7 after infection. No
serum samples were collected on day 8, but samples from the
two remaining positive animals were negative for viral genome
on day 9. There was no significant difference in the peak levels
of viremia, as measured by rRT-PCR, between any of the
different MAb-treated groups (P  0.297 by analysis of vari-
ance with a general linear model). Live virus was isolated from
serum samples of animals treated with anti-CD4 and anti-CD8
MAbs up to 4 days postinfection and from animals treated with
anti-WC1 and control MAbs up to 3 days postinfection. No live
virus or viral genome was detected in probang samples at
postmortem examination by virus isolation and rRT-PCR
(data not shown). FMDV capsid protein was detected by im-
munofluorescence confocal microscopy in germinal centers of
mandibular lymph nodes harvested from all animals at post-
mortem examination (data not shown).
Effect of lymphocyte depletion on virus-neutralizing anti-
body. The results of virus-neutralizing antibody assays of serum
samples are shown in Fig. 5. Titers of 45 (considered posi-
tive) were attained by 5 days postinfection in all four control
animals, by 4 to 7 days in the animals treated with anti-CD4
MAb, and by 5 to 6 days in the animals treated with the
anti-WC1 and anti-CD8 MAbs. There were no obvious differ-
ences in the onset of detectable neutralizing antibody in the
calves receiving the different antibody treatments. In particu-
lar, the onset of detectable neutralizing antibody titers postin-
fection was not significantly different in the calves treated with
anti-CD4 antibody and those treated with control antibody
FIG. 3. Effect of lymphocyte depletion on development of clinical
FMD. The clinical scores, consisting of rectal temperature and clinical
signs of FMD (see Table S1 in the supplemental material), are dis-
played for experiment 1 animals (a) and experiment 2 animals (b). The
data related to the anti-CD4 MAb-treated animals are highlighted in
blue.
FIG. 4. Effect of lymphocyte depletion on viremia. The viral genome was detected by rRT-PCR in serum samples collected from day 0 to 7 and
day 9 postinfection. Genome copies per ml serum are displayed for anti-CD4 MAb treated-animals (a) and TRT3 control MAb-treated animals
(b) from both experiments and for anti-WC1 MAb-treated (c) and anti-CD8 MAb-treated (d) animals from experiment 1.
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(P  0.11 by Kruskal-Wallis test). The complete data set of
virus-neutralizing antibody titers can be found in Table S2 in
the supplemental material.
Effect of lymphocyte depletion on the isotype of FMDV-
specific antibody responses. Serum samples collected daily
during the first 7 days of infection and at 2- to 5-day intervals
up to day 29 (experiment 2) or day 30 (experiment 1) postin-
fection were analyzed using an ELISA with reagents specific
for bovine IgM, IgG1, and IgG2 to determine the kinetics of
the various isotypes generated by the FMDV-specific antibody
response. Comparison of the kinetics of antibody titers over
time by parallel curve analysis (see statistical analysis) did not
reveal any statistically significant differences between the
responses of animals in MAb-treated groups and those in
the control MAb-treated groups (Fig. 6). IgG antibody iso-
types were detected 5 to 7 days after infection, indicating
rapid isotype switching in all animals. Indeed, in some cases,
specific IgG2 antibodies were detected earlier than IgM
antibodies. Antibody isotype class switching occurred during
the phase of CD4 T-cell depletion in animals that received
anti-CD4 MAb.
Effect of lymphocyte depletion on the response to FMDV
nonstructural proteins. Serum samples collected at 3- to 6-day
intervals, from day 0 to day 29 (experiment 2) or day 30 (ex-
periment 1) postinfection, were analyzed for the presence of
antibodies against the FMDV nonstructural protein 3ABC.
The kinetics of the antibody response to 3ABC in animals
receiving anti-CD8 or anti-WC1 MAb were similar to that of
the control animals, with antibody initially being detected on
days 6 to 16, and maximum titers were detected on day 29 or
30. In contrast, three out of the four anti-CD4 MAb-treated
animals had no detectable antibodies against 3ABC through-
out the 29 to 30 days, and the fourth animal (VT75) remained
FIG. 5. Effect of lymphocyte depletion on virus-neutralizing antibody. Virus-neutralizing antibody titers are displayed for anti-CD4 MAb-
treated (a) and TRT3 control MAb-treated (b) animals from both experiments and for anti-WC1 MAb-treated (c) and anti-CD8 MAb-treated (d)
animals from experiment 1. A titer of 45 is considered to be positive.
FIG. 6. Effect of lymphocyte depletion on the isotype of FMDV-
specific antibody responses. Examples of the FMDV-specific antibody
isotype profiles are displayed for an anti-CD4 MAb-treated animal (a)
and for a TRT3 control MAb-treated animal (b) from experiment 2. ‚,
IgG1; , IgG2; }, IgM. The CD4 cell population was depleted from
the lymphoid tissue of experiment 2 anti-CD4 MAb-treated animals on
study day 5 postinfection, and circulating CD4 lymphocytes were
depleted from anti-CD4 MAb-treated animals in both experiments up
to at least 7 days postinfection (9 days postinfection for animal VT74).
Efficient antibody isotype class switching occurred during the period of
CD4 T-cell depletion.
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negative until day 29. Titers of anti-3ABC antibodies in serum
samples obtained at the time of postmortem examination (day
29 or 30) are shown in Fig. 7. These results indicate that the
depletion of CD4 T cells during the phase of acute FMDV
replication ablates the antibody response to nonstructural viral
proteins.
Effect of lymphocyte depletion on the antibody response to
G-H loop peptides. Serum samples from animals receiving
anti-CD4 MAbs and those receiving the control MAbs in both
experiments were examined using an indirect ELISA for the
presence of IgG antibodies to O UKG/34/2001 and O1BFS
VP1135-156 peptide, which represent a superficial loop exposed
on the surface of the viral capsid. No antibodies directed
against the peptides were detected prechallenge. Titers of an-
tibody specific for the O UKG/34/2001 peptide detected prior
to the reappearance of circulating CD4 T cells following
depletion (day 7 postinfection for experiment 1 and day 9
postinfection for experiment 2) (Fig. 1) and following CD4
T-cell repopulation (day 16) are displayed in Fig. 8. By the end
of the period of CD4 cell depletion, the four infected control
animals all showed detectable antibody responses to the O
UKG G-H loop peptide at day 7 (experiment 1) or day 9
(experiment 2). In contrast, antibody was undetectable in two
of the CD4 T-cell-depleted animals and present at a very low
titer in the other two depleted animals at these time points. By
day 16, the titers of antibody in three of the depleted animals
were still lower than those in the controls. These findings were
corroborated by the data for the O1BFS peptide (data not
shown), indicating that the antibody response to the G-H loop
was inhibited by CD4 T-cell depletion.
DISCUSSION
Our results confirm that the depletion of CD4 lymphocytes
from the blood circulation and superficial lymph nodes can be
achieved in cattle by administering specific mouse MAbs. The
application of different CD4 depletion protocols in calves dur-
ing the early stages of infection with FMDV was found to
result in a similar, substantial ablation of IgG antibody re-
sponses to nonstructural viral proteins but had little impact on
the antibody responses to sites on the surface of the virus
particles that induce neutralizing antibodies. The depletion of
CD4 T cells also had no significant effect on the course of
viremia or the clinical severity of disease associated with
FMDV infection. Milder clinical scores were recorded for one
of the CD4-depleted animals (animal RZ53); however, it is
unlikely that this observation is significant considering the
spectrum of clinical signs seen after FMDV challenge (3).
There was no CD4 T-cell depletion in control animals follow-
FIG. 7. Effect of lymphocyte depletion on the response to FMDV
nonstructural protein 3ABC. By day 29 or 30 postinfection, three
anti-CD4 MAb-treated animals had no detectable antibody response
to FMDV nonstructural protein 3ABC. Samples were considered pos-
itive if the percentage of inhibition was 50 (64). Control, TRT3
MAb-treated animals from both experiments; CD4, anti-CD4 MAb-
treated animals from both experiments; WC1, anti-WC1 MAb-treated
experiment 1 animals; CD8, anti-CD8 MAb-treated experiment 1 an-
imals.
FIG. 8. Effect of lymphocyte depletion on antibody response to FMDV O UKG/34/2001 G-H loop peptide. No antibodies directed against the
peptide were detected prechallenge. (a) IgG antibody responses of experiment 1 CD4-depleted animals to FMDV O UKG/34/2001 VP1135-156 G-H
loop peptide were completely absent or substantially less than those of the control animals by day 7 postinfection. By day 16, a stage when CD4
cells were repopulating (Fig. 1), the titers of antibody in the CD4-depleted animals were less than or equal to those of the controls. (b) The antibody
response of experiment 2 CD4-depleted animals was similarly absent or substantially less than that of the control animals by day 9 postinfection.
Although CD4 cells were repopulating by day 16 postinfection, the response of the experiment 2 CD4-depleted animals was still substantially less
than that of the controls.
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ing FMDV infection (see Fig. S1 in the supplemental mate-
rial), which contrasts with the significant lymphopenia re-
ported for swine following FMDV infection (6). We have also
shown in separate studies that there is no generalized immu-
nosuppression during the acute phase of FMDV infection in
cattle or a loss of specific T-cell populations (data not shown).
Capsid-induced T-cell recall responses are detectable after
FMDV infection (12, 28). However, we have also shown that
an FMDV-specific CD4 T-cell response is not detectable for at
least 12 days after FMDV infection (data not shown), making
the analysis of FMDV-specific T-cell responses during the pe-
riod of depletion of little value in the present study. The ani-
mals in the high-dose antibody treatment group were immu-
nized with commercial bovine herpesvirus vaccine (Tracherine;
Schering-Plough, United Kingdom) approximately 1 month
prior to the start of these studies. Unsurprisingly, the specific
proliferative response to bovine herpesvirus antigen was not
detectable in animals during the treatment with anti-CD4
MAbs.
Although the administration of anti-WC1 antibody was also
found to result in a profound depletion of circulating WC1 
T cells, such a depletion did not have any measurable effects on
the course of infection with FMDV or specific antibody re-
sponses to the virus. The role of these cells in protection
against infectious agents in ruminants is unclear. They are
found extensively in the epithelium (34) and have been pro-
posed to play a role in intracellular infection, promoting a
Th1-biased immune response (52) and non-MHC-restricted
NK-like cytotoxicity (11, 20). Previous reports of WC1 T-cell
depletion studies with cattle have shown an enhanced antibody
response to nonreplicating antigen and an enhanced periph-
eral blood mononuclear cell-proliferative response to nonspe-
cific mitogens in animals depleted of this population (34).
These results were supported further by the detection of en-
hanced local and systemic antibody responses following respi-
ratory syncytial virus infection in WC1-depleted calves (68).
By inspection, one cannot rule out a minor influence of WC1
cell depletion on the duration of viremia as measured by rRT-
PCR (Fig. 4), although it was not possible to assess the signif-
icance of this observation due to the small group size. Overall,
our findings suggest that WC1  T cells do not play a major
role in the resolution of clinical signs and control of viremia
after acute FMDV infection in cattle.
The application of the same protocol to deplete CD8 T
cells was less successful, resulting in only a partial depletion of
the circulating population, which had no discernible effect on
the response to FMDV. This result is consistent with previous
evidence that the MAb-mediated depletion of bovine CD8 T
cells is more difficult to achieve than for other T-cell subsets
(46, 49, 68, 69). Therefore, it was not possible to conclusively
evaluate the influence of CD8 T cells on the course of infec-
tion with FMDV or early responses to the virus. However, a
partial depletion of CD8 T cells did not affect the resolution
of acute FMDV infection.
Antiviral antibody responses may be classified as T depen-
dent (T-D) or T independent (T-I) based on the requirement
for T-cell help for antibody production. T-I type I antigens are
mitogenic agents that activate Toll-like receptors to elicit
polyclonal B-cell activation. Type II T-I antigens are com-
plex structures, typically rigid two-dimensional arrays com-
prising epitopes displayed at 5- to 10-nm intervals, that engage
and cross-link the immunoglobulin receptors on the surface of
B cells, generating strong activation signals. These stimulatory
activities result in antibody production in the absence of spe-
cific T-cell help but may depend upon accessory signals from
antigen-presenting cells or T cells for B-cell activation (5, 30,
43, 44). Some viral capsids fall into this category. However,
nonoligomerized viral proteins released from dying cells or
disrupted virus particles generally act as T-D antigens.
The T dependency of antibody responses of cattle to a num-
ber of defined antigens and viral pathogens has been confirmed
in several previous studies (33, 46, 68). CD4 lymphocyte
depletion with MAb doses as low as 0.3 mg/kg has been shown
to result in a significant reduction in the antibody response of
calves to human red blood cells and ovalbumin (34, 46). The
same dose of MAb administered to calves subsequently in-
fected with respiratory syncytial virus resulted in a marked
suppressive effect on the antibody response and increased viral
pathology (46, 68). Similar results have been reported after
infection with noncytopathic bovine viral diarrhea virus, where
incomplete circulating CD4 lymphocyte depletion resulted in
a delayed antibody response and longer duration and higher
titer of circulating virus (33). Furthermore, the depletion of
CD4 lymphocytes in cattle previously vaccinated with com-
mercial FMDV vaccine has been shown to ablate T-cell-pro-
liferative responses to FMDV antigen, indicating a depletion
of memory T cells (46). While Naessens et al. (46) previously
depleted blood and splenic CD4 cells with 0.2 mg/kg MAb,
they needed 2 mg/kg to deplete CD4 cells from peripheral
lymph nodes. It is therefore likely that our own work with 2.58
mg/kg was effective at depleting the cells from peripheral
lymph nodes, which was confirmed in our analyses of prescapu-
lar lymph nodes. Moreover, the present work clearly demon-
strated that such a depletion had a strong influence on the
anti-FMDV immune response, but this was prejudiced depen-
dent on the antigenic determinants against which the humoral
response was mounted. A particularly significant feature of the
present study was the finding that CD4 T-cell depletion re-
sulted in an ablation of antibody responses to nonstructural
proteins in three of the four animals examined while leaving
intact the antibody responses to sites on the surface of the viral
capsid. This is consistent with the notion that antibody re-
sponses to these antigenic components are T-D and T-I, re-
spectively. The development of a delayed antibody response to
the nonstructural proteins in one of the CD4-depleted calves
may be the result of low-level replicating virus still being
present in this animal when CD4 T-cell function was re-
stored.
Our findings are consistent with previously published results
using the FMDV murine experimental model, where the pro-
tective immune response was shown to be T-I (8, 40). Early T-I
protection and the production of antibody have been described
for a number of other cytopathic viruses including vesicular
stomatitis virus and influenza virus infection in mice (22, 38). A
number of other picornaviruses have also been shown to act as
T-I antigens (4). The T-I nature of these viral antigens is
thought to be a result of their rigid, highly repetitive, and
highly organized structure (5). Also, the magnitude of the T-I
immune response and augmentation of isotype switching has
been shown to correlate with the degree of antigen organiza-
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tion and the dose of antigen reaching the secondary lymphoid
organs (4, 41, 47, 72). One of the key protective mechanisms to
prevent the dissemination in the host of acute cytopathic vi-
ruses is the rapid induction of neutralizing antibodies (5). It
has also been proposed that the surface antigenic structure of
acute cytopathic viruses has evolved to stimulate early T-I
antibody responses in order to limit the extent of viral infection
and avoid rapid death of the host. Conversely, B-cell responses
may have evolved to deal with such threats. The dynamics of
infection with FMDV in cattle is consistent with the model
described above, with infection being rapidly controlled and
animals usually showing clinical signs for only a few days.
Clearly, T-D antibody responses are also stimulated by these
acute cytopathic viruses and are likely to be responsible for the
production of affinity-maturated IgG isotype antibodies and
long-term memory (30).
Although FMDV shares structural features with other pi-
cornaviruses, there is one unique feature that distinguishes
aphthoviruses including FMDV from other picornaviruses: the
absence of a canyon or pit which places the integrin cell at-
tachment site in the protruding, fully exposed, highly disor-
dered, and mobile immunogenic G-H loop (1). Previously re-
ported studies with virus-specific MAbs, coupled with
structural analyses of FMDV particles, have identified five
antigenic sites on the FMDV capsid, including the G-H loop,
which are involved in virus neutralization (18). The G-H loop
is considered highly immunogenic, and immunization of cattle
with synthetic peptides representing the loop has been shown
to induce neutralizing antibody and, in some cases, protection
against viral challenge (66). However, recent data describing
VP1 G-H loop-substituted chimeric vaccines indicates that the
G-H loop may not be required for producing a strong neutral-
izing antibody response or a protective immune response fol-
lowing vaccination of cattle (24). In the present study, although
CD4 T-cell depletion had no discernible effect on the overall
neutralizing antibody response, it substantially inhibited the
IgG antibody response against the G-H loop peptide. The
neutralizing antibody in these animals was presumably directed
against the other sites on the viral capsid. Our data suggest that
the high degree of mobility of the G-H loop may result in it
being less effective as a T-I type II antigen than the other
antigenic sites, which have a more stable conformational struc-
ture. Antibodies directed against the G-H loop were detected
in all CD4 T-cell-depleted cattle after the phase of depletion
albeit at lower levels than in infected control animals. Al-
though circulating virus was no longer detectable at this time,
the detection of FMDV capsid antigen in mandibular lymph
node germinal centers at postmortem examination indicates
that there remained a source of antigen for induction of G-H
loop-specific antibody when CD4 T-cell function was re-
stored.
The induction of IgG after FMDV immunization has been
shown to be T-D in a murine experimental model (16). These
results have been confirmed in vitro in a mouse model in which
FMDV-infected dendritic cells could directly stimulate B lym-
phocytes to secrete FMDV-specific IgM, but T-cell help was
required to induce class switching toward IgG (50). Compari-
son of the kinetics of the FMDV-specific antibody response of
experiment 1 and 2 animals over time did not reveal any sta-
tistically significant differences between the depleted groups
and the control MAb-treated groups. Specific IgM was de-
tected from 4 days postinfection, and specific IgG1 and IgG2
were detected from 5 days postinfection, consistent with re-
ports by other investigators (14, 21, 58). Our results show that
in vivo, in a natural ruminant host, FMDV infection can induce
not only a specific and rapid IgM response but also efficient
and rapid isotype class switching in the absence of CD4 T
cells. The ability of T-I viral antigens to induce efficient class
switching in the absence of T-cell help is thought to be related
to the repetitiveness of the viral antigens (5) and the formation
of antigen-specific germinal centers by a T-I process in the
absence of T-cell-derived CD40 ligand (26). T-I B-cell prolif-
eration and isotype class switching in mice following exposure
to type II T-I antigens have been shown to be dependent on an
intact follicular dendritic cell network and signaling through
CD40 on the surface of B cells and follicular dendritic cells.
The signaling through CD40 is dependent on complement,
specifically through C4b binding protein in the absence of the
T-cell-derived CD40 ligand CD154 (9, 26, 48, 60, 65). We have
shown previously with cattle that FMDV localizes to germinal
centers as early as 3 to 4 days postchallenge (35), a process that
may provide the signals required for T-I isotype class switching
and an early FMDV-specific IgG response (26, 47). The tumor
necrosis factor family ligands BAFF and APRIL have also
been shown to contribute to CD154-independent antibody iso-
type switching, germinal center maintenance, and T-I antibody
responses (59). In addition to these potential mechanisms in
the CD4 T-cell-depleted cattle exposed to FMDV, gamma
interferon produced by  T cells (41), NK cells (36, 65), or
activated B cells (51, 71) may also provide alternative but less
efficient support for CD154/CD4 T-cell-independent isotype
switching by acting directly on B cells potentially in the absence
of specific germinal center formation (62).
In conclusion, the results of this study indicate that func-
tional CD4 T cells are not required, either to provide help for
antibody production or as antiviral effector cells, for the effec-
tive control of primary infection with FMDV in cattle. Isotype
switching of the antibody response was also found to be inde-
pendent of CD4 T cells. The current studies do not identify
whether CD4 T cells play a role in the development or du-
ration of a memory response or contribute to the efficacy of
immunity to subsequent viral challenge. Further studies are
required to address these questions, possibly using similar de-
pletion protocols in vaccinated animals.
A number of molecular approaches to FMD vaccine devel-
opment have been used since the mid-1970s, including the use
of viral subunit proteins, protein fragments, and peptides, iso-
lated from viral particles or produced in bacteria, baculovirus,
and transgenic plants or as synthetic peptides (10, 29, 66). A
general problem with most subunit vaccines is that they do not
elicit a protective immune response comparable with that in-
duced by live virus or killed whole-virus vaccines (66). Peptide
vaccines based on the G-H loop (70) do not appear to fully
mimic the conformation of the native B-cell epitopes and stim-
ulate antibody of rather narrow specificity, which appears to be
T-D (19, 25, 42). In contrast, studies of responses to traditional
FMDV vaccines, which utilize intact inactivated virus, have
shown that they stimulate rapid antibody responses that can
provide protection against disease within 4 to 5 days. The
results of the current study, together with other findings, indi-
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cate that the preservation of the complex three-dimensional
structure of the FMDV capsid is critical for inducing rapid and
effective antibody responses. This is consistent with current
thinking on the development of safer and more effective vac-
cines based on the use of empty viral capsids produced using
recombinant DNA constructs.
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